New drug cocktail aims to tackle Hard-to-Treat colorectal cancer
NCT ID NCT06558773
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding eliglustat (a GSL synthetase inhibitor) to standard treatments can help shrink tumors or slow cancer growth in people with advanced colorectal cancer that has not responded to at least two prior treatments. About 120 participants will be randomly assigned to one of three groups: regorafenib plus an immune checkpoint inhibitor, eliglustat plus an immune checkpoint inhibitor, or all three drugs together. The study will also look at changes in the immune system and tumor environment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eliglustat (Cerdelga) combined with an immune checkpoint inhibitor and/or regorafenib (Stivarga)
What this could lead to
If successful, this could offer a new treatment option for people with advanced colorectal cancer that has not responded to standard therapies.
What could go wrong
This is an early phase 2 trial with only 120 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China
RECRUITINGBeijing, Biotherapeutic Department of Chinsese PLA Gereral Hospital, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••